Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.

MLA

Fujimoto, Daichi, et al. “Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 13, no. 3, Mar. 2018, pp. 377–86. EBSCOhost, https://doi.org/10.1016/j.jtho.2017.11.123.

APA

Fujimoto, D., Sato, Y., Uehara, K., Ishida, K., Fukuoka, J., Morimoto, T., Kawachi, H., Mori, R., Ito, M., Teraoka, S., Nagata, K., Nakagawa, A., Otsuka, K., Imai, Y., & Tomii, K. (2018). Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 13(3), 377–386. https://doi.org/10.1016/j.jtho.2017.11.123

Chicago

Fujimoto, Daichi, Yuki Sato, Keiichiro Uehara, Kaori Ishida, Junya Fukuoka, Takeshi Morimoto, Hayato Kawachi, et al. 2018. “Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 13 (3): 377–86. doi:10.1016/j.jtho.2017.11.123.